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MY THIRTY-FIVE YEAR VIEW OF ORGAN TRANSPLANTATION 
Thomas E. Starzl 
In my earlier historical reassessments 
(1-3) and those of Caine (4,5), Murray (6), 
Moore (7), and Groth (8), the dawn of 
transplantation was defined as the turn of 
this century, in part because these reviews 
emphasized kidney transplantation. Kahan 
has exposed the incompleteness of this 
perspective by tracing the roots of 
transplantation into antiquity (9). Not-
withstanding the early traces, evolution of 
the modern field is a phenomenon of the 
last 40 years. During the first part of this 
time, I picked up the trail of renal transplan-
tation and sta.rted a new one with liver re-
placement. From 1958 onward, liver 
transplantation played an increasingly 
prominent role in generic advances that 
were applicable to all organs. 
The first known attempts of kidney 
transplantation in humans were made in 
France and Germany between 1906 and 
1923 using pig, sheep, goat, and monkeys 
or apes for donors (10-12, translation for 
11,12 provided in 10). The first human-to-
human kidney transplantation was reported 
in 1936 by the Russian, Yu Yu Voronoy (13, 
translation provided in 10). The technique 
of renal transplantation which became 
today's standard was developed inde-
pendently by three different French sur-
geons, Charles Dubost (14), Rene Kuss 
(15),and Marceau Serve lie (16) and 
reported in 1951. A number of the kidneys 
were taken from criminals shortly after their 
execution by guillotine. John Merrill, the 
Boston nephrologist had seen the French 
operation while travelling in Europe in the 
early 1950s as was later mentioned by the 
surgeon, David Hume (17) in his description 
of the beginning (in 1951) of the Peter Bent 
Brigham kidney transplant program. It was 
adapted later for the historically important 
identical and fraternal twin cases in Boston. 
Although immunosuppression was not 
available, patients of R.H. Lawler of 
Chicago (18) and Hume and Merrill (17) 
may have derived some benefit. In Hume's 
patient, the kidney graft which was placed in 
the thigh produced urine for five months. 
PHASE I (1955 to 1958) 
Although oblivious to transplantation 
during most of this time, I began experi-
ments in hepatic physiology which led 
directly to the first efforts in 1958 to replace 
the liver in dogs. These were stimulated by 
a clinical observation while I was an assis-
tant reSident in training at the Johns Hop-
kins Hospital in Baltimore (1952 to 1956). 
In 1955, I helped Dr. Alfred Blalock (Chair-
man of Surgery) perform a splenorenal 
shunt on a mildly diabetic rum manufacturer 
from Jamaica whose diagnosis was cir-
rhosis of the liver. Afterwards, the patient 
no longer needed insulin to control his blood 
sugar. 
I wondered if this was because the 
patient's natural insulin coming from his 
pancreas into the portal vein had been 
bypassed around the liver and was there-
fore made either more effective or more 
available. The idea became irresistible 
when I. Arthur Mirsky, a biochemist from the 
University of Pittsburgh, suggested at about 
the same time that insulin action was regu-
lated by a hypothetical liver enzyme which 
he called insulinase. Mirsky speculated that 
diabetes was a disorder caused by too 
much insulinase and the consequent need 
for insulin overproduction. 
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The idea was tested by animal ex-
perimentation at the University of Miami 
where I finished my general surgical 
residency in 1956 to 1958. Because there 
was no large animal facility at this new 
medical school, I set one up with 
homemade metabolic cages in an empty 
garage across from the Emergency Room 
of the Jackson Memorial Hospital. We ob-
tained dogs from the city pound, made them 
diabetic with alloxan, calibrated their insulin 
requirements after they became diabetic, 
and eventually performed portacaval shunt. 
To my dismay, the insulin requirements after 
operation increased drastically instead of 
diminishing as I had hoped (19). In addi-
tion, the animals quickly developed the pre-
viously well-known syndrome of "meat 
intoxication." Now, I became convinced that 
a different metabolic relationship than I had 
envisioned must exist between the 
pancreas (by virtue of its insulin) and the 
liver. In further experiments, various kinds 
of blood were used for portal venous inflow. 
Everything we tried then (19) and for a long 
time later (20-22) failed to unmask the kind 
of insulin-liver relationship which I was look-
ing for. 
The questions about sugar and insulin 
metabolism raised by these still primitive 
thoughts and investigations would require 
better models, including one of total 
hepatectomy in large animals. While still in 
Miami, I developed an improved method of 
total canine hepatectomy (23) which soon 
replaced previously used techniques in 
other laboratories. A fringe benefit was my 
realization that a new liver for the pursuit of 
metabolic studies could be installed (I 
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thought easily) in the empty space from 
which the normal liver had been taken. 
Work on this possibility was begun in 
earnest after I relocated in Chicago in June 
1958. 
While I wasted time in Miami during 
1956 to 1958 doing physiologic experi-
ments, efforts in transplantation were going 
on elsewhere. There was no way of 
preventing rejection and without such treat-
ment, clinical transplantation could succeed 
only between monozygotic twins. This step 
was taken two days before Christmas 1954, 
with a kidney transplantation from an identi-
cal twin donor by Murray et al (24). It was 
the first example of successful transplanta-
tion of a vital whole organ and had a major 
impact on the field as described elsewhere 
(2). However, further progress in all other 
situations would require immunosuppres-
sion. 
Peter Medawar's appreciation that 
rejection was an immunologic phenomenon 
(25,26) made inevitable the efforts to alter 
the immune system to prevent this process. 
As early as 1951, Rupert Billingham, work-
ing with Medawar and Peter Krohn, showed 
that corticosteroids delayed skin graft rejec-
tion in animals (27,28). Then, w.J. 
Dempster of Hammersmith Hospital, Lon-
don, showed that steroids ameliorated es-
tablished acute rejection after kidney 
transplantation in dogs (29), presaging the 
clinical response to this kind of "rescue" 
therapy that later would soon be seen in 
many thousands of patients. Dempster also 
was the first to show the immunosuppres-
sive effects of total body irradiation (30). 
PHASE II (1958 to 1961) 
The ostensible purpose of returning to 
Northwestern Medical School (where I had 
graduated in 1952) was to become fully 
qualified to do thoracic surgery. This was 
going to be another paSSing fancy. I had al-
ready foregone a promising career in 
neurophysiology in which I had obtained a 
Ph.D., only to abandon this field and to work 
for a year and a half in heart physiology 
preparatory to work in cardiac surgery. 
Now, I was training to be a thoracic sur-
geon, after having already lost interest in 
this field. Because the thoracic surgery 
load was light, I immediately resumed the 
canine hepatectomy experiments and 
during July 1958, the first liver transplanta-
tions were performed at the VA Research 
Hospital. This was a project to which I paid 
more and more attention as time went by 
after hearing from John Lewis, my thoracic 
surgery chief at Northwestern, that Norm 
Shumway, Lewis' previous cardiac surgery 
fellow at the University of Minnesota, had 
begun attempts to replace the dog heart at 
that institution. 
A four-page application was sent to the 
National Institutes of Health and resulted in 
funds of about $30,000 a year for five years. 
An unexpected further boost came during 
the summer of 1958 when Dr. John A.D. 
Cooper, Associate Dean of Northwestern 
Medical School, asked me if I wanted to be 
the school's candidate for a Markle Scholar-
ship. It was an unusual honor because 
there could be only one nominee from each 
of the 100 or so medical schools in North 
America. From the pool of nominees, 20 to 
25 would be chosen. Those selected com-
mitted themselves to academic careers as 
opposed to private practice. 
The criteria by which the candidates 
were chosen was not obvious. Fortunately, 
the judges who were not scientists were in-
sufficiently informed to know how bizarre 
my proposed career plan was. It is amusing 
to recall that the committee at the Markle in-
terviews from February 2 to 5, 1959, saw no 
reason at all why my proposal of liver 
transplantation could not be accomplished. 
I was given the Markle scholarship and a 
few months later began a junior faculty ap-
pointment. 
Free from patient responsibilities for the 
first time in four and one-half years, I started 
on July 1, 1959 to work in the laboratory full 
time. With grant money in hand, the liver 
transplant project was transferred from the 
VA laboratory to the University surgery 
laboratories in the Montgomery Ward Build-
ing at 303 Chicago Avenue. Two senior 
149 
medical students named Bob Lazarus and 
Bob Johnson and a third year surgical resi-
dent named Harry A. Kaupp Jr., joined the 
team. Within a few weeks, liver transplanta-
tion, which I had been dOing alone for the 
preceding year, including anesthesia 
management, was perfected enough to 
have the dogs live through the operation on 
a regular basis. The secrets were simple. 
First, the liver was preserved by core 
cooling with cold saline or lactated Ringer's 
solution which was infused into the portal 
vein at the same time as the liver blood 
supply was interrupted in much the same 
way as practiced clinically tOday except for 
the solution (31). The second key require-
ment was a veno venous bypass sytem 
during the anhepatic period when the native 
liver was being removed and the vessels of 
the new organ were being anastomosed to 
those of the recipient. Otherwise, the con-
sequence of simultaneously obstructing 
both the portal vein and inferior vena cava 
for the necessary 30 to 60 minutes was irre-
versible injury to the intestines and other 
splanchnic viscera. With the use of plastic 
bypass tubes which effectively decom-
pressed the obstructed venous beds, the 
main blood vessels supplying and leaving 
the liver could be anastomosed with less ur-
gency. The vascular anastomoses were 
sophisticated ones but well within the grasp 
of trained surgeons. Biliary reconstruction 
also was a conventional procedure. 
Thereafter, liver transplantation could 
be done with a reasonable expectation of 
short-term survival until rejection occurred. 
By the end of the summer of 1959, we were 
confident that this operation was not only 
feasible, but could someday be applied for 
the treatment of human disease. We had 
heard by now that a similar project, which 
also was begun in the summer of 1958, was 
underway at the Peter Bent Brigham Hospi-
tal under the direction of Francis D. Moore. 
Our work on canine liver transplanta-
tion and that by Moore's Boston team was 
not generally known until the annual meet-
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ing of the American Surgical Association 
(ASA), held at White Sulphur Springs, West 
Virginia on April 5, 1960. A paper on the 
Boston results was read by Moore and pub-
lished the following autumn in the Annals of 
Surgery (32). As a guest of the society, I 
discussed Moore's paper (33), based on our 
impending publications in Surgery, Gynecol-
ogy, and Obstetrics (31,34), the journal of 
the American College of Surgeons. Moore 
had presided over the early trials of kidney 
transplantation at the Brigham. He ex-
pected that what was being learned with the 
kidney model would be applicable to other 
organ transplants and vice versa. So did I. 
Moore was reporting on 31 liver 
transplant experiments. Seven of his 
animals lived for more than four days, with a 
maximum of 12 days before death from 
rejection. From these seven animals, he 
had pieced together a very complete picture 
of the postoperative course after liver re-
placement in the untreated dog. In my dis-
cussion, I described how in more than 80 
experiments we had systematically tested 
different ways of restoring the transplanted 
liver's blood supply including the omission 
in some dogs, and the augmentation in 
others, of portal venous inflow. This was a 
reflection of my original interest in interor-
gan metabolic relationships. Livers which 
were given a normal portal venous inflow 
performed better than those which were not. 
The important practical achievement for the 
moment was that we had 18 dogs with sur-
vival greater than four days, with one animal 
living for 20 and one-half days. 
During this meeting, two friendly young 
men whose faces I recognized introduced 
themselves in the lobby of the Greenbrier 
Hotel. One was Dave Hume, the former 
Harvard surgeon who had started the Peter 
Bent Brigham Hospital kidney transplant 
program but who now was at the Medical 
College of Virginia. With him was Dick Eg-
dahl, and after a few minutes we were 
joined by John Mannick, who would soon 
move to Richmond with Hume. In 1978, 
Mannick would succeed Moore as Chief of 
Surgery at the Brigham. Although they ex-
pressed interest in my work, I was far more 
intrigued by theirs. 
Just before Moore's presentation, 
Hume, Egdahl, Charlie Zukoski and three 
other COlleagues had given a paper on kid-
ney transplantation in dogs which had been 
conditioned with total body irradiation (35). 
The work provided a remarkable insight into 
the difficulties to be overcome if there ever 
was to be clinical value of any whole organ 
transplantation procedure. When Hume's 
dogs were given more than 1000 rads, 
rejection of the kidneys could be prevented, 
but they all died of overwhelming infection. 
With smaller doses, the grafts were 
rejected. There was no margin of safety. 
It seemed to me that Hume's paper 
(which Moore discussed) had the same 
negative implication for clinical use. Hume 
agreed and told me that he and two of his 
coworkers (Charlie Zukoski and H. M. Lee) 
were experimenting with a new drug called 
6-mercaptopurine as a substitute for x-ray 
therapy. Six weeks earlier they had sent an 
abstract with encouraging results to the Sur-
gical Forum committee of the American Col-
lege of Surgeons, to be considered for the 
annual meeting in San Francisco the follow-
ing October. 
This was the first of many personal or 
phone conversations with Hume, of which 
the last was at the American Surgical As-
sociation meeting at the Century Plaza 
Hotel, Los Angeles, in April 1973, a few 
weeks before he was killed in an airplane 
crash. He always reminded me of a human 
buzz saw, constantly advancing but with 
such preCision and beauty of motion that it 
was a masochistic thrill to realize that the 
cutting pathway was directed straight to 
you. Few people passed through the 
veneer and were allowed to see behind. A 
very friendly and generous man was hiding 
there. 
Both Zukoski's abstract and one of 
mine were accepted for presentation at the 
1960 fall meeting of the American College 
of Surgeons to which Hume had referred. I 
had gone beyond simple liver transplanta-
tion in that other organs were being 
transplanted with the liver in what was 
called multivisceral transplantation (36). In-
stead of facing its new recipient environ-
ment alone, the liver was accompanied by 
the donor stomach, intestines, and 
pancreas. Since these were the organs 
which drained into the portal vein, the 
transplanted liver could bring with it its own 
supply of insulin, food, and the other sub-
stances which a few years hence would be 
called hepatotrophic factors. 
Only five animals survived the difficult 
operation, but in each one rejection of the 
individual organs was less than would be 
expected if they had been transplanted by 
themselves. Because the large grafts 
contained lymph nodes, spleen, and other 
elements which are part of the normal 
immune system, it was not surprising to 
find cells throughout the recipient's own 
tissues which were thought (but not 
proved) to have migrated from the graft, 
reflecting graft-versus-host disease (GvHD) 
(37). It would be another 13 years before 
the extent of GvHD, even with transplanta-
tion of the intestine alone, would be worked 
out in rats by the Massachusetts General 
Hospital surgeons, G.J. Monchik and Paul 
Russell (38). 
My enthusiasm about the multivisceral 
transplant project was put into the deep 
freeze by the discussion that followed my 
talk. William Longmire of UCLA deflated 
any illusions I might have had about its im-
portance. He asked wryly if it might be 
easier than performing this complex opera-
tion to simply anesthetize the dog and have 
a laboratory assistant carry the animal from 
one table to another. The ripple of laughter 
from the audience completed the humilia-
tion. 
Longmire was implying what I already 
knew, that any such research, including that 
involving liver transplantation alone, was a 
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technical exercise unless a means could be 
found of controlling rejection. StimUlated by 
Hume's report earlier in the year (35), I had 
already tried to depress the immune system 
with x-ray therapy before liver transplanta-
tion. Irradiation of liver grafts had no benefi-
cial effect and irradiation of the reCipient 
was overtly harmful (39). 
The faint hope that remained was the 
6-mercaptopurine Hume had mentioned to 
me earlier and which Caine had described 
the previous February in two dogs which 
had survived for 20 and 47 days after 
similar kidney transplant operations (40). At 
another Surgical Forum session on the 
same day as my presentation, Zukoski 
reviewed the evidence from Hume's Rich-
mond team that kidney graft rejection was 
weakened and delayed by this drug (41). 
His results, along with those from earlier 
skin graft experiments in rats (42,43), and 
the independent observations by Caine 
provided hope where there had been none 
before. 
The hope was dim because only a 
small minority of animals could be kept alive 
for as long as one month, and none of the 
kidney recipients had truly long survival. In 
principle, the dilemma was not different than 
with x-ray therapy, although the possibility 
remained that there was a better 
therapeutic margin. It was also obvious that 
liver transplantation was much too compli-
cated an operation to use for studies of im-
munosuppression. The road to the liver 
would have to lead through the kidney. 
Knowing that Joe Murray's Brigham re-
search team was screening immunosup-
pressive drugs in Frannie Moore's surgical 
laboratory (Caine would be coming there in 
1961), I approached Moore as we walked 
down the street after one of the forum ses-
sions. I asked him if he would accept me 
for a research sabbatical in Boston, effec-
tive immediately if possible. The fact that I 
was a Markle scholar gave me a small 
financial hedge since these funds 
($6,000tyear for five years) could be trans-
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ferred between universities. I had not dis-
cussed the matter with anyone for the 
simple reason that leaving Northwestern 
had not occurred to me until that day. 
I can remember how firm Moore was, 
but also how kind, as he denied my request. 
I became (and stili am) indebted to Moore 
for his decision which, because it was nega-
tive, moved me on to an entirely new level 
of development and responsibility. Four-
teen months later, I left Chicago to be an 
Associate Professor of Surgery at Colorado. 
On March 27, 1962, less than three months 
after arriving in Denver, I performed our first 
human kidney transplantation on a patient 
who is still alive 29 years later. Eleven 
months after that on March 1, 1963, came 
the first attempt at human liver replacement. 
As I had concluded in San Francisco, the 
road to the liver would lead through the kid-
ney, but I would have to find a pathway 
myself by becoming involved in the renal 
field. 
Deciding to leave Chicago in the space 
of one day in San Francisco was easier 
than actually doing it. I had no place to go 
nor any prospects because I had not been 
planning to move. However, it seemed to 
me that the next step in transplantation 
would not be possible where I was. After a 
year of exclusively experimental work, I had 
begun to see private patients in the summer 
of 1960. The practice grew uncontrollably 
but almost ali of it was being done in private 
hospitals rather than the Northwestern 
University hospitals. Overnight, I had be-
come a commercial surgeon and by so 
doing had freed myself from debt for the 
first time in more than 10 years. But the 
time and energy to accomplish this had 
been stolen from the research program 
which was the justification for my Markle 
scholarship. 
A way out was found for me by Ben 
Eiseman, who was Chairman of the Depart-
ment of Surgery at the University of Ken-
tucky. William R. Waddell, the newly 
appointed Chairman of Surgery at the 
University of Colorado, was looking for 
someone to fill the position of Chief of 
Surgery at the Denver VA Hospital, an ap-
pointment held by Eiseman until his depar-
ture for Kentucky. This was one of the best 
nonchairman jobs in the United States. 
Eiseman recommended me to Waddell who 
subsequently came to Chicago in the sum-
mer of 1961 to discuss the possibility. Wad-
dell wanted transplantation to be an imprint 
of his new department. Although he had no 
experience in the field, his long stay in Bos-
ton had exposed him to the much publicized 
activities at the Brigham. His own affiliation 
at Harvard always had been at the Mas-
sachusetts General Hospital, 'but he was 
friendly with Dave Hume, Joe Murray, and 
Frannie Moore. 
We agreed on the goal of bringing liver 
transplantation to clinical use. However, we 
also realized that it could not be attempted 
until kidney transplantation, an operation 
which had almost universally failed until that 
time, could be made to work. I told him that 
no single agent or drug, would allow us to 
accomplish anything more than had been 
done by the pioneers whose efforts in the 
kidney field are described in other contribu-
tions to this volume. 
To avoid a false start, we would follow 
the tracks of Joe Murray and John Merrill 
(24) by beginning with an identical twin case 
in which immunosuppressive treatment was 
not necessary. Waddell, whose move to 
Denver in July 1961 preceded mine by al-
most six months, knew of a 27-year-old 
patient who had a potential identical twin 
donor. The potential reCipient was being 
cared for at a Denver private clinic. The at-
tending physician had promised to hold his 
patient for transplantation until my arrival, 
instead of sending him to Boston as he 
originally planned. 
Waddell and I placed a high priority on 
duplication of the Northwestern transplant 
laboratory at the VA animal facility which 
was essentially unused by surgeons follow-
ing the mass exodus of Colorado faculty 
during the preceding year. The laboratory 
had been cannibalized by other depart-
ments, and nothing was left for us except 
for a small operating room with a kennel 
across the hall that could accommodate 30 
or 40 dogs. 
What we aspired to seemed like lunacy 
to some of the people whom we recruited to 
the transplant team from the existing faculty 
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in January 1962. In spite of these doubts, 
the identical twin transplantation went for-
ward in March 1962. Both the donor and 
recipient teams had practiced the operation 
many times on cadavers in the morgue, and 
by the time of its performance there was lit-
tle reason for anxiety. The result was per-
fect (44). Both the patient and his donor 
remain well more than 29 years later. 
PHASE III (1962 to 1963) 
At the time of our identical twin 
transplantation, artificial kidney machines 
had appeared in the United States but were 
used primarily to tide patients over during 
an acute but reversible bout of renal failure 
(7). Transverse incisions to insert the plas-
tic tubes into the patient's vessels for con-
nection to the machine would start at the 
wrists, moving upward every few inches to 
find new access sites until the axillae were 
reached. Each site was used three or four 
times. When the arms were used up, the 
incisions would start at the feet and move 
up to the groins. Once the leg vessels were 
exhausted, the string had played out. 
This was changing after the introduc-
tion in 1960 of the Schribner shunt for 
chronic dialysis at the University of 
Washington. However, blood vessel access 
was not the only problem. In 1962, very few 
artificial kidneys were available. The prob-
lem was dramatically publicized in Life 
magazine, November 9, 1962, by pictures 
of a tribunal in Seattle deliberating on which 
six patients among many candidates should 
be selected for entry into the only artificial 
kidney unit in the world equipped for chronic 
care (45). 
Dr. Joe Holmes, the Chief of Nephrol-
ogy at the University of Colorado, had the 
eqUipment, skill, and experience to use the 
new technology. Approaching 60 years, he 
became the oldest member of the 
transplantation team. Chronically fatigued 
by overwork and lung disease which he ag-
gravated by constantly smoking cigarettes, 
he fought to treat or hold back the tide of 
desperate patients who flocked to Colorado 
General Hospital after the publicity of our 
identical twin transplantation. 
One of these patients with renal failure 
was a 12-year-old Black boy named Royal 
Jones. His arrival was too early, because 
we were not ready to treat him and would 
not be for another half year. Holmes agreed 
to try to hold Royal Jones on dialysis and 
the countdown began. The VA transplanta-
tion laboratory for which we had been slow-
ly acquiring equipment and personnel 
sprang into action. It was possible within a 
few weeks to perform eight or 10 dog kid-
ney transplantations in a day or twice this 
number if necessary. A supply of the 6-mer-
captopurine or its derivative BW 57-322 (Im-
uran), which was receiving its first trials at 
the Brigham, was obtained from George 
Hitchings of the Burroughs Wellcome drug 
company. 
We were particularly interested to see if 
x-ray therapy could be combined with Im-
uran since the only genuinely promising 
results of which we had knowledge in other 
than twin cases were those of the French 
teams of Rene Kuss (46) and Jean Ham-
burger (47). They had used irradiation. 
However, in our dogs given total body ir-
radiation at the same levels planned for 
Royal Jones a disquieting effect was seen. 
Many of the canine kidneys quickly became 
enormously swollen and cyanotic, seeming-
ly worse than in untreated animals. Only an 
occasional animal had prolonged survival. 
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The results were the same as Hume had 
reported in dogs (35). Our pessimism was 
reinforced by the discouraging results in the 
clinical irradiation trials at the Brigham 
(48,49). 
The best results were with Imuran. 
Some of these dog recipients lived on for 
years, long after discontinuance of therapy. 
It was demonstrated unequivocally that 
prednisone therapy could reverse rejection 
but caused death from its own side effects 
of which ulceration and bleeding from the 
intestinal tract were almost invariable (50). 
These observations were not published until 
long after the clinical steroid trials were un-
derway (51). Our conclusion by the autumn 
of 1962 was that survival for 100 days or 
more with any single agent could be 
achieved in only one of every four or five 
mongrel dogs. There had been no time to 
test all of the treatment combinations. 
What to do with this incomplete infor-
mation, and with similar observations 
reported by Caine and Murray from the 
Brigham laboratories at the Surgical Forum 
in October 1961 (52), was our quandary. 
Adequate hemodialysis for Royal Jones 
was becoming more difficult daily because 
of exhaustion of his access sites. The 
transplantation with a kidney from his 
mother went forward on November 24, 
1962, with combination treatment by irradia-
tion, Imuran, and prednisone. 
To protect him from infection, he was 
kept in one of the Colorado General Hospi-
tal operating rooms for a month afterwards 
during which he had a moderately severe 
rejection which was reversed easily with 
large doses of prednisone. A few weeks fol-
lowing this, he returned to school. The 
transplant lasted until 1968, and then was 
replaced with a second graft. Many years 
later, the second graft also failed. Royal is 
still alive awaiting his third kidney nearly 29 
years later. 
The success could have been a fluke. 
During the next 12 weeks, three more kid-
ney transplantations were performed but 
--- ------------------
omitting total body irradiation. Two of these 
patients who were treated with Imuran and 
prednisone also are alive, both with their 
original grafts from a brother or sister. The 
third patient named Bill Sinclair died of in-
fection 113 days postoperatively. After the 
transplantation, a large thrombus in one of 
his leg veins migrated to his pulmonary 
artery from where the embolus was 
removed at an emergency operation by Dr. 
Tom Marchioro, now Professor of Surgery at 
the University of Washington. Sinclair 
never fully recovered but his new kidney, 
which had been donated by his wife, func-
tioned well until the end. It seemed to us 
that the immune barrier now had been sur-
mounted repeatedly. The stage was set for 
liver transplantation. It never would be this 
easy again, in part because our strategy in 
the kidney program had emphasized the 
use of related donors and in part because 
liver transplantation was a vastly more dif-
ficult operation. 
The first attempted liver transplantation 
on March 1, 1963, ended in tragedy. The 
patient was a 3-year-old child with biliary 
atresia which had brought him to the 
miserable last days of his life in a condition 
which today might be considered beyond 
help by transplantation. The donor was 
another child who died during an open heart 
operation. In looking back, one can ask 
why the liver recipient, who himself was on 
life support with a ventilator, should not 
have donated a heart to the other child in-
stead of receiving his liver. 
The question did not come up because 
the first heart transplantation in Capetown 
was four years in the future. Instead, the 
donor who already was on a heart-lung 
machine was cooled while the artificial cir-
CUlation was maintained. Although we had 
performed nearly 200 liver transplantations 
in dogs, nothing could have prepared us for 
the difficulties in the recipient which were 
caused by portal hypertension, scarring 
from previous operations, and a complete 
lack of clotting. The patient bled to death. 
During April and May 1963, more kid-
ney transplantations were performed. Of 
the first six nontwin recipients, four were 
destined to survive for the next quarter cen-
tury. By now, research in the laboratories 
turned back to the more difficult operation of 
liver transplantation. The main lesson that 
had been learned from the first liver case 
was that the defective blood clotting found 
with terminal liver disease would have to be 
controlled. A German coagulation expert 
named Kurt von Kaulla who was working in 
the Department of Surgery was recruited to 
the team. Von Kaulla recommended 
strategies to shore up defective clotting fac-
tors with infusions of purified blood products 
and to control fibrinolysis with epsilon amino 
caproic acid (EACA). 
In 1962 and early 1963, the University 
of Colorado did not have the high visibility in 
the national media which it later enjoyed, or 
labored under. Only when Bill Waddell an-
nounced it while discussing a paper given 
by Hume in April 1963 at the American Sur-
gical Association in Phoenix, Arizona did the 
existence of the Colorado kidney program 
become generally known (53). Before then, 
Waddell was in contact with Joe Murray and 
his other friends at the Brigham in Boston. 
Dave Hume called me almost daily from 
Richmond for information about the course 
of our patients. Both Murray and Hume 
seemed interested only in the kidney cases. 
The failed first attempt at liver transplanta-
tion went unnoticed by the press. 
At the 1963 American Surgical Associa-
tion meeting, I met Will Goodwin, one of the 
world's foremost urologists and a pioneer in 
transplantation in his own right. Several 
years earlier, Goodwin had attempted 
several kidney transplantations at UCLA. 
From these cases, a number of important 
observations were made which would be of 
great help to later workers. The death of all 
his recipients had discouraged him and 
caused him to stop clinical trials. 
In one of Goodwin's patients, he had 
seen reversal of kidney rejection by steroids 
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in a woman who also was treated with the 
anticancer drug, cyclophosphamide (54). 
She survived for 160 days and was the first 
example of long survival of a human who 
was treated with drugs only, using a drug 
combination that was extensively evaluted a 
decade later (55). Goodwin's historic kid-
ney transplantation was in September 1960. 
However, the observation of steroid respon-
siveness was not published until 1963 and 
was unknown to me. After talking to Good-
win in Phoenix, I added a discussion of 
Goodwin's case to our paper but failed to 
annotate the basic literature on steroid im-
munosuppression (27-29) and the clinical 
observations on steroid therapy previously 
made by Kuss (46) and Hamburger (47). 
This was unintentional neglect. 
Beginning in 1962, we had been using 
Imuran plus prednisone, and our conviction 
was that prednisone was the dose 
maneuverable component of this first ver-
sion of modern day immunosuppression. 
The Imuran-steroid combination was the 
secret of our unexpected success and in 
our manuscript containing this message 
(51), we emphasized two other points: the 
reversibility of kidney rejection with high 
dose steroid (prednisone) treatment, and 
the "tolerance" which allowed lightening of 
maintenance immunosuppression in the 
weeks and months after a successful kid-
ney transplantation. 
While we talked in Phoenix, Goodwin 
told me of an impending meeting on renal 
transplantation in Washington, DC, 
scheduled for September at the National 
Research Council. He said that he would 
arrange invitations for me and for Bill Wad-
dell. A few days later, Goodwin came to 
Colorado. I learned later that his habit was 
to glean information from these informal 
visits and to report it in memoranda to the 
UCLA transplant group which included Paul 
Terasaki. More than 27 years later, in 
November 1990, a urologist named Jac-
ques Poisson of Nice, France gave me a 
yellowed copy of a six-page single-spaced 
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intramural letter from Goodwin which Pois-
son had saved from his fellowship days with 
Goodwin in Los Angeles. Dated May 11, 
1963, the in-house document started: 
"Dear Friends: On May 5 and 6, I 
visited Denver to learn what I could of the 
homotransplantation effort of the group 
there (Tom Starzl, William Waddell, Tom 
Marchioro, Oliver Stonington, and about a 
dozen others). The visit was most impres-
sive to me, and I should like to share some 
of my impressions with you. 
When I arrived on the evening of May 
5, I went to the Veterans Hospital where I 
visited the completion of what must surely 
be the world's first technically successful 
homotransplantation of the human liver. 
The recipient, a patient of Dr. Waddell's, 
was a man with a primary hepatoma involv-
ing the whole liver. He had had two ex-
plorations, 7 days and 1 day before the 
transplant. He was a non-veteran admitted 
to the VA Hospital in order to receive the 
transplant from a VA patient dying there of a 
brain tumor. The surgical team was waiting 
alerted for 48 hours, one of the drawbacks 
of cadaver donor transplantation. 
When the white donor (the recipient 
was Afro-American) finally died, Dr. Mar-
chiaro and his team promptly introduced a 
catheter via the femoral vessel and began 
perfusion (up into the aorta) at a slow rate 
with a heart-lung machine that was primed 
with refrigerated oxygenated glucose solu-
tion plus procaine. Later they opened the 
chest and also perfused the lower aorta and 
abdominal organs from above. 
Preparation of the sterile donor liver 
took about 2 hours. Approximately, another 
2 hours were spent in transplanting the liver, 
performing all the necessary anastomoses. 
When I saw the homotransplant in place, it 
had a good color and looked like a normal 
liver. A cholecystectomy was done and the 
gall bladder bed bled in a healthy normal 
way. A T-tube was placed in the common 
duct below the anastomosis and shortly 
thereafter, it began to drain clear bile. The 
above surgical procedures were done . . . 
with great skill and careful speed. . .. They 
had tried this some weeks or months ago in 
a child with congenital atresia of the bile 
ducts. The procedure failed because the 
recipient bled to death under their eyes. 
There was lack of blood clotting. Because 
of this awesome previous education, they 
were prepared in the present case, and 
gave large amounts of human fibrinogen in-
travenously during the operation. 
The next day, I saw and talked with the 
patient. His new liver was making large 
amounts of clear bile and he seemed to be 
in good immediate postoperative condition. 
It seemed to me that the patient was in bet-
ter shape than the surgeons on the day 
after this monumental effort. " 
The rest of Goodwin's letter was con-
cerned with the kidney recipients, many of 
whom he interviewed. As it turned out, the 
patients to whom he talked are still alive. 
Goodwin went on: 
"The Denver team has either 8 or 9 
successful kidney transplants (2 or 3 since 
dead) . .. Another patient I was privileged 
to see is a 35 year old male who had come 
from Virginia to the Denver VA because he 
was told that the Denver and Los Angeles 
VA Hospitals were "centers" for kidney 
transplantation. Denver was closer than 
Los Angeles, but somehow he got past 
Richmond and Hume. He received a kid-
ney from his 32 year old sister in January, 
1963. Before that, he had dialysis in Vir-
ginia (at the VA Hospital), and in Denver in 
preparation for the transplant. He appeared 
to be in excellent health. He had a moon 
face and ruddy cheeks. He confessed to an 
interest in sex and erections but evaded the 
question of whether or not he had inter-
course (he is a bachelor). He apparently is 
presently a ward of the VA, and is being 
rehabilitated. I think that he takes Imuran 
and prednisone and I believe that he 
formerly had chronic glomerulonephritis. 
He was a truck driver. " 
This patient also is still living with his 
graft which is the longest surviving nontwin 
kidney transplant in the world. It is interest-
ing that there was an ABO blood group mis-
match. He was B blood type and his sister 
donor was A. 
A cadaver organ procurement program 
was a necessary condition for the Denver 
program and particularly interested Good-
win. Brain death and the concept of the 
heart-beating cadaver were five years away. 
Consequently, all donors were without a 
heart beat and circulation for five to 30 
minutes before an artificial circulation could 
be restored with a heart-lung machine 
(56,57). Goodwin had not heard of this 
method and wrote: 
"Tom Marchioro has worked out and is 
the driving force behind an active and intel-
ligent program to haNest cadaveric organs 
(especially kidneys) for homotransplanta-
tion. .. A very low pressure system is used 
with low rates of perfusion (aortic) so that 
the blood inflow (to the pump) matches the 
output. They feel that this is valuable and 
useful and have had some good animal ex-
perimental data to support them . .. A visit to 
their dog lab at the VA Hospital was most 
impressive. It is a well run, active place, air 
conditioned, and clean. They have plenty of 
technical help. They keep superb records 
on their animals, similar to regular hospital 
charts. They have one doctor in full time 
charge of records alone. They have a num-
ber of excellent kidney transplant experi-
ments going on to test the value if any of 
splenectomy, thymectomy, etc. They also 
have an active program with liver 
transplants. " 
Goodwin's six-page single-typed 
memorandum is too lengthy to reproduce in 
its entirety, but near its end was a comment 
about the interactions within any multidis-
Ciplinary group, showing Goodwin's grasp of 
human behavior: 
"One of the interesting human aspects 
of this work, not only in Denver but 
everywhere, is how much each participant 
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wants to be a part of the team and how 
each of us speaks so readily of "our ex-
perience, " while privately considering it "my 
experience." Everyone with whom I speak 
is eager and ready to give credit where due, 
and at the same time wants to ensure his 
own niche and his own credit. " 
Reading his report nearly 28 years 
later, I wondered if Goodwin might have set 
new standards in journalism had he not 
committed himself to surgery. He saw 
everything that was significant. The clotting 
problem had been dealt with in the liver 
recipient whom he observed, and the kind 
of management during operation which he 
described became standardized over the 
years. However, the strategy of coagulation 
control had a delayed backfire in this case 
and in the next three liver transplant 
recipients who followed. During the time 
when the livers were sewed in, the plastic 
external bypasses were used to reroute 
venous blood around the area of the liver in 
the same way as had been worked out in 
dogs. 
In the humans who were being given 
drugs and blood products to promote clots, 
these clots formed in the bypass tubing and 
passed on to the lungs. There, they caused 
abscesses and other lung damage which 
contributed to or was the cause of delayed 
death of not only the patient seen by Good-
win (who died 22 days later) but in three 
more recipients who had otherwise suc-
cessful liver transplants in June, July, and 
October 1963 (57,58). A pall settled over 
the liver program, and no more patients 
were entered for more than three years. It 
was the beginning of a self-imposed 
moratorium. By this time, single patient tri-
als had failed at the Brigham (59) and in 
France (60). 
When Goodwin left Denver in early 
May 1963, he realized the regUlarity with 
which rejection could be controlled in kidney 
recipients using the Imuran-prednisone 
treatment. However, in his lectures, he al-
ways warned "Don't promise more than you 
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can deliver," and illustrated the point with 
the photograph of an ancient statue of one 
of the Greek gods who was sparsely clad. 
Wrapped around the god's leg was a volup-
tuous maiden, expressing some unfulfilled 
desire, the nature of which was left to the 
amused audience's imagination. 
Throughout the spring and summer of 
1963, our pace of kidney transplantation in-
creased, and the series had reached 30 by 
the time of the Washington kidney 
transplant meeting in September 1963. 
This conference to which Waddell and I 
were belatedly invited was a small one, with 
only about 25 contributors. However, al-
most all of the key workers were there who 
had brought the field this far. Here, I first 
met Joe Murray, John Merrill, and other 
members of the distinguished Brigham 
group. The French and English pioneers 
also were there including Ralph Shackman, 
Ken Porter, and Roy Caine. I was uneasy 
and felt like someone who had parachuted 
unannounced from another planet onto turf 
that was already occupied. 
By this time, I had started writing a 
book, Experience in Renal Transplantation 
(61), which was to be published the follow-
ing summer. In its introduction which al-
ready was in the hands of the printer, I 
already had summarized the work of these 
men. After describing the dismal record to 
date, it went on: 
"... Despite these encouraging findings, 
it was not yet possible to obtain consistent 
success with homotransplantation proce-
dures, either in experimental animals or 
man. Like the elusive jigsaw puzzle, in 
which many of the pieces had been fitted 
into their appropriate slots, the picture was 
not yet complete. The pioneer efforts of 
Murray, Kuss, Hamburger, and Hume had 
all demonstrated that a renal homo-
transplant was capable of protracted func-
tion in the occasional case. If this could be 
achieved sporadically, it seemed 
reasonable to expect that the proper 
manipulation of a number of small details 
might provide a consistently successful 
solution. Despite this expectation, almost 
all renal homotransplants had failed when, 
in the spring of 1963, Goodwin and Martin 
compiled the known renal transplants from 
various centers throughout the world. Less 
than 10 per cent of those cases treated to 
that time had survived for as long as three 
months. The courageous and often tragi-
cally unsuccessful attempts of the early 
pioneers provided a vast, although frequent-
ly uncatalogued, background of valuable in-
formation upon which future progress might 
be built . .. " 
These were the kidney transplant 
pioneers. What we had done was to com-
plete their story. At the same time, we real-
ized for the first time in Washington that we 
had more surviving kidney transplant 
recipients than everyone else combined. 
Determining the eventual outcome of these 
patients would be important. This was 
made possible by the creation at the con-
ference of a worldwide kidney transplant 
registry, which would be based in Boston. 
The impetus for this extraordinary compila-
tion came from Joe Murray. 
The meticulousness of the registry 
report (62) made it possible 25 and one-half 
years later in the summer of 1989 to trace 
the fate of all 342 nontwin kidney reCipients 
who had undergone transplantation 
throughout the world from the beginning up 
to the end of March 1964 (63). There were 
24 25-year survivors, of whom 15 were from 
our original Colorado series. The nine 
others were still alive at six other centers. 
These included three of Dave Hume's 
original patients at the Medical College of 
Virginia, two from the University of Min-
nesota (Kelly and Lillehei), and one each 
from Boston (Murray), Cleveland (Koltt), 
Edinburgh (Woodruff), and Paris (Ham-
burger). 
In this look-back, none of the world's 24 
quarter-century survivors had been given an 
unrelated donor kidney. Nor was there an 
example in the world of a 25-year survival of 
a cadaver kidney allograft (63). One of 
Hamburger's cadaver kidney recipients in 
Paris finally passed this barrier on October 
12, 1989. This was not surprising. Inferior 
results with unrelated donors were evident 
even at the time of the Washington meeting. 
Because liver and heart grafts could be 
obtained only from cadaver donors, what 
had been learned so far was not an invita-
tion to go forward with the extrarenal trials. 
Better anti rejection treatment than the Im-
uran-prednisone combination must be 
developed or else a means had to be found 
to better match up the donors to the im-
mune system of the recipient (tissue match-
ing). Apart from the deaths that already had 
occurred, this was the main reason why the 
liver program was closed for three more 
years. Our primary mission of liver 
transplantation had failed. Instead of intro-
ducing a new treatment for liver disease, we 
had succeeded only in making kidney 
transplantation practical. Not long after, 
Waddell remarked that we had climbed onto 
the wrong tiger and would find it hard to get 
off. I soon understood how right he was. 
After the Washington meeting, several 
of the conference members came to Denver 
for a first hand look: Hume, Porter, Shack-
man, Kuss, and Kuss' young associate, 
Jacques Poisson. While there, Porter 
agreed to write the section on kidney 
transplant pathology for my impending book 
on renal transplantation. His chapter was a 
classic which was years ahead of the field. 
Before long, his interest turned to liver 
transplantation and stayed there for the next 
28 years. 
Elsewhere, the kidney gold rush began. 
At the beginning of 1963, the only active 
kidney transplant programs in the United 
States were at the Brigham, in Richmond, 
and at the University of Colorado. More 
than 25 new ones sprang up in the United 
States alone within the next year. We were 
inundated with fellowship applications, 
providing a talent pool from which came 
many of the leading figures in transplanta-
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tion of the next generation. Kidney 
transplantation seemed to have become a 
clinical service overnight. 
This was partly an illusion. It would not 
be possible for many more years to safely 
transplant cadaveric organs of any kind, in-
cluding the kidney. Well into the late 
1970's, Terasaki reported a compilation 
from 105 American programs of nearly 
5,000 cadaveric kidney cases in which the 
one-year graft survival was only 45 percent 
with an average patient mortality of nearly 
20 percent (64). Individual centers tended 
not to report their own poor results, er-
roneously believing that everyone else must 
be doing better. 
During the peak of the professional 
euphoria, many major hospitals had ac-
quired artificial kidney capability, with the 
result that patients who would have died 
only one or two years earlier could be kept 
in reasonable condition while they waited 
for a transplant. Serving their needs was al-
most entirely dependent on live donors be-
cause brain death as a condition for 
cadaveric donation was five years in the fu-
ture. Desperate potential recipients were 
piling up faster than places could be found 
for them for dialysis support, a service for 
which most health insurance agencies 
refused to pay because it was "experimen-
tal." 
At the height of the crisis, hetero-
transplantation was reexplored. On 
February 16, 1963, Dr. Claude Hitchcock of 
Hennepin County Hospital, Minneapolis, 
transplanted the kidney of a baboon to a 65-
year-old woman. The organ functioned for 
four days before its artery clotted (65). The 
case was not made public until it was 
learned laffir in 1963 of a far more en-
couraging experience by Dr. Keith 
Reemtsma of Tulane University using the 
the closer-to-human chimpanzee donor 
(66). One of Reemtsma's chimpanzee kid-
ney grafts functioned for nine months. 
Reemtsma also transplanted a Rhesus 
monkey kidney which was fiercely rejected. 
----------------------------------------
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Convinced that his own first failure was 
due to a defective surgical operation and 
that the baboon would be an acceptable 
kidney donor for humans, Hitchcock called 
me about exploring this possibility for our 
patients with urgent need. He already had 
a strong collaboration with the Southwest 
Primate Foundation, an outstanding primate 
center in San Antonio, Texas. Baboons 
were bred there, and their medical records 
were kept for their life time. Infecting 
patients with baboon diseases seemed un-
likely. An international consortium of 
primate experts descended on Denver. 
Six patients were given the baboon kid-
neys at Colorado (67). All of the organs 
functioned promptly and maintained func-
tion for 10 to 60 days. However, the neces-
sary doses of Imuran and prednisone were 
very high, and eventually the grafts were 
rejected. As judged by Porter, the rejection 
was midway in severity between that of the 
chimpanzee and Rhesus kidneys but not 
qualitatively different than in some 
homografts in which there was a humoral 
component. The same events were 
recapitulated two decades later in the Baby 
Fae baboon-to-human heart transplantation 
in spite of much improved immunosuppres-
sion (68). It was clear that the use of 
animal organs would have to wait for better 
and possibly fundamentally different im-
munosuppression. The chimpanzee would 
be excluded from future consideration be-
cause of the threat to its extinction and be-
cause its anthropomorphic qualities were 
increaSingly recognized (69). 
PHASE IV (1964 to 1966) 
After the dust settled, a new era began 
- this one of consolidation, confirmation, and 
sober reflection about what had been done. 
Will Goodwin, whose memorandum of May 
1963, was quoted in Phase IV, now wrote 
another one to his UCLA team, reflecting 
the amazing events in the intervening 11 
months. Like the first document, this one 
was found in Nice, France, in the 
memorabilia which Jacques Poisson had 
saved. After a lengthy description of the 
papers (many on transplantation) given at 
the 1964 American Surgical Association 
(April 1-3, Hot Springs, Virginia), Goodwin 
concluded: 
" .. . It seems to me that we are now in a 
kind of "second phase." Many have more 
confidence than before and are beginning to 
look for longer range successes. At the 
same time, we should go slowly to study 
and observe some of these strange things 
that are being seen, such as peripheral 
neuropathies and vascular lesions, etc. I 
would not be surprised if one of the most in-
teresting things that could come out of all of 
this will be observations of what may turn 
out to be "new diseases" in some of these 
long range survivors. " 
Goodwin was prophetic. The most ob-
vious derivative diseases were those 
caused by the steroids which were essential 
for consistent success: redistribution of 
body fat with moon facies and the typical 
"buffalo hump," growth arrest in children, 
damaged and thinned skin with abdominal 
stretch marks, cataracts, bone 
demineralization and jOint decay, myopathy, 
peripheral neuropathy, and secondary 
diabetes. The quality of the reCipients' lives 
as well as freedom from lethal opportunistic 
infections were inversely related to the 
amount of steroid therapy needed to retain 
function of their new kidneys. It was soon 
learned that low steroid dose requirements 
could be expected only if the donor was a 
family member. 
Even under these circumstances, it 
was tempting to bring to conferences or 
symposia only those patients who had been 
recently operated upon, before the stigmata 
of steroid treatment became visible. A fur-
ther specter emerged when several of our 
earliest recipients developed a malignant 
tumor (then called a reticulum cell sarcoma, 
later classed as B-cell lymphomas) in the 
brain, liver, or elsewhere (70). It was soon 
apparent that these and other cancers 
would be seen in increased numbers in 
these patients (71,72). Israel Penn, now 
Professor of Surgery at the University of 
Cincinnati, began a worldwide registry of 
these cancers in transplant recipients; at the 
end of 1990, more than 5,000 had been 
entered. The complication was attributed to 
the loss of immunologic surveillance, but 
evidence supporting this hypothesis was at 
first marginal (72). Years later, after the 
demonstration that the Epstein-Barr virus 
caused the B-cell lymphomas, it was shown 
that these lymphomas usually involuted 
when immunosuppression was stopped 
(73). 
Appreciation that kidney transplantation 
was a still imperfect new form of treatment 
was a powerful stimulus to find better ways 
of immunosuppression, or else to find ways 
to improve tissue matching and thereby 
reduce the amount of immunosuppression 
which was needed. Strategies to achieve 
both objectives were put in place during a 
half year moratorium on new kidney cases 
which was decided on in Colorado, begin-
ning in the spring of 1964. Ripples from 
these strategies can still be seen almost 
three decades later. 
The first step was a trial of tissue 
matching. What to measure, and how, were 
unanswered questions. We already had 
shown the importance in kidney transplanta-
tion of compatibility of the ABO blood group 
antigens. About half of the ABO incom-
patible kidneys were rejected within minutes 
or hours, presumably because of binding of 
the isoagglutinins to ABO antigens in the 
cells and blood vessel endothelium of the 
kidney grafts. From this experience came 
the rules of ABO compatibility for kidney 
transplantation (74), which later were shown 
to apply to the liver, heart, and other solid 
organs (75). 
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Beyond ABO matching, it was 
predicted by many of the Washington con-
ference partiCipants of 1963 that tissue 
matching would improve the reliability and 
predictability of rejection control. Felix 
Rapaport, one of the conference members, 
already was a star in transplantation be-
cause of his work in histocompatibility. Paul 
Terasaki's name was frequently mentioned 
in such discussions because he recently 
had developed his microcytotoxicity techni-
que which he thought detected histocom-
patibility antigens in the lymphoid cells. The 
concept was the same as that advanced 
earlier by Dausset (76) using a different an-
tibody detection system and subsequently 
supported by collaborative investigations 
with Rapaport. 
Workers in Holland, Italy, Denmark, 
England, and the United States began to 
search for other antibodies, believing that 
by back tracking the antibodies, they might 
be able to identify the tissue antigens which 
had evoked them. If this were pOSSible, the 
practical next objective would be to match 
up these antigens in donors with the an-
tigens of prospective recipients. This was 
the beginning of human histocompatibility 
research, a new field of indescribable im-
portance and complexity which made intel-
ligible many previous mysteries of the 
human immunologic system and certain 
aspects of immune rejection of transplants. 
By 1963, the list of antibodies which 
seemingly reacted with different human tis-
sue antigens was long enough to convince 
Terasaki that matching efforts in future 
cases might be worthwhile. However, he 
wanted to begin by studying the antigens in 




Rh- to Rh+ 
Rh+ to Rh- I Relatively safe 
A to non-A I Dangerous 
--~ 
B to non-B __ -1 Dangerous 
AB to non-AB I DanQerous 
*0 is universal donor, AB is universal 
recipient [Reproduced from (74)]. 
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patients bearing successfully transplanted 
kidney grafts, comparing those with the an-
tigens in their donors, and seeing if there 
was any relation of the fit of the antigens 
with the clinical outcome. A positive correla-
tion of good matching and good outcome 
would establish that the antigens being 
studied second hand through their reaction 
with the antibodies were the crucial ones in-
volved in rejection. This was Terasaki's 
hypothesis and that of Dausset and 
Rapaport. 
Knowing from Goodwin's report from 
the Washington conference that most of the 
kidney transplant survivors were in Denver, 
Terasaki came to Colorado after the meet-
ing, rounded up the recipients and their 
donors, drew blood samples, and estimated 
the antigen match with his still impure and 
incompletely classified antibody panel. To 
everyone's delight, many of the most 
trouble-free recipients were those whose 
white cell antigens closely matched those 
on the donor's white cells. The clue was 
tenuous because there were so many ex-
ceptions and also because most of the suc-
cessfully transplanted kidneys came from 
sibling donors or from parents who had 
donated to their children (77). 
The retrospective study was finished by 
autumn and when our kidney program was 
reopened in October 1964, it included the 
first effort ever made at prospective match-
ing (78). At the time, kidney donation in 
Colorado was still being accepted from 
volunteer convicts at the Canon State 
Prison who were numerous enough in many 
cases to allow a choice amongst as many 
as 50 or 60. In spite of the size of the unre-
lated donor pool, it was difficult to find a per-
fect or even good match whereas very 
complete matches were encountered fre-
quently if there were multiple potential 
donors within a family. 
The results when the transplantations 
were actually performed were disappointing. 
The matching in unrelated cases, although 
never complete, was better than that pre-
viously achieved by chance when no such 
efforts had been made. However, no dif-
ference could be seen in the recovery of 
patients who received kidneys from these 
relatively well-matched versus completely 
mismatched donors or in the histopathology 
of the grafts which were graded by Porter 
after biopsy. 
The results were reported as "prelimi-
nary" in 1966, but by 1969, I was alarmed 
by the continued lack of correlation between 
clinical outcome and quality of matching in 
unrelated cases (by now largely cadaver 
donors) and concerned about my role in 
starting these epidemic efforts at matching 
five years previously and spurring them on 
subsequently. We collected clinical data on 
all of our patients in whom we had tissue 
typing information from the beginning of our 
Colorado program in 1962 until the present 
and arranged the first of several grueling 
work sessions at Terasaki's laboratory. The 
conclusion was that typing was not a dis-
criminating instrument of donor selection 
using unrelated donors, that it could be 
used to select ideal donors within families, 
and that short of perfect matches, it was 
only equivocally helpful even within families. 
Reports of these results at nephrology 
and surgery meetings (79) created a furor in 
the typing fraternity. The evidence was that 
the antigens being matched were transplant 
antigens which followed classical genetiC 
(Mendelian) laws (witness the sibling 
results) but that the system was so complex 
(more than we were measuring) that match-
ing would not be the boon we had 
predicted. Terasaki suspected that there 
might be a "center effect" in which ex-
perience and skill with immunosuppression 
covered up a typing effect or that the 
sample size was too small to test the 
original hypothesiS. 
He set out to collect 1,200 cases from 
multiple centers. The original conclusions 
were validated and the new analysis was 
presented by Terasaki to the Transplanta-
tion Society in The Hague on September 8, 
1970. Anxious and looking smaller than I 
remembered him, Paul walked resolutely to 
the podium and read his message to a huge 
and it seemed to me hostile audience. 
When he finished, there was little applause. 
Within a few weeks, the federal agency 
funding Terasaki's UCLA laboratory paid it 
an emergency site visit and discontinued its 
support. Terasaki's heretical report was not 
welcome, and now the messenger must be 
killed. Before long, others came forward 
with evidence that Terasaki's conclusions 
were correct. Terasaki had been right not 
only about what typing could do, which was 
considerable for intrafamilial transplantation, 
but what it could not do in less than perfect-
ly matched cadaveric cases. Twenty years 
later, the only controversy is whether match-
ing under all other circumstances means 
enough to be the primary determinant of 
cadaver kidney distribution. Shom of his 
govemment contract, Terasaki saved his 
laboratory by other means. Full of honors 
now, he has remained to haunt the per-
petrators of the inequity for the next two 
decades (80). 
By exposing the truth, Terasaki had 
made it clear that improvement in clinical 
transplantation would depend primarily on 
better drugs and other improved treatment 
strategies, not by vainly hoping that the 
solution would be through tissue matching. 
Although it was not appreCiated at the time, 
Terasaki's conclusion breathed life into the 
still struggling fields of liver and heart 
transplantation since patients needing these 
organs did not have recourse to artificial 
organ support analogous to the artificial kid-
ney while they waited for a well-matched 
donor. It was a relief to know that the selec-
tion of donors with random tissue matching 
would not result in an intolerable penalty. 
Ironically, the supreme practical con-
tribution of tissue typing proved to be the 
detection of those cytotoxic antibodies 
which attracted Terasaki's attention in the 
first place. At the First Histocompatibility 
Tissue Matching Conference (June 7-8, 
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1964, in Washington DC), Terasaki 
described how these antibodies if directed 
against the cells of the donor can cause hy-
peracute kidney rejection in the same way 
as with blood group mismatches (81). 
He recommended the cytotOXiC 
crossmatch test which is carried out today 
before every kidney transplantation 
anywhere in the world. The credit for this 
major contribution often is given to some-
one who was in the 1964 audience and 
reported the same thing almost two years 
later. When the details of hyperacute rejec-
tion were worked out later, including the 
similarity of this catastrophe to the 
Schwartzman reaction (82), Terasaki was a 
collaborator, and in the late 1970s he 
defined the kinds of antibodies which were 
dangerous and which were not. 
The tissue matching strategy was 
played out in the clinics. In contrast, im-
provement of immunosuppression was a 
laboratory project from 1963 until the first 
clinical trials of ALG were begun in 1966. 
However, the first order of business was an 
Imuran project with liver transplantation. 
Our original premise of developing a kidney 
transplant program as a pathfinder for the 
technically more difficult liver procedure (83) 
came into question. When no one was able 
to obtain truly long survival in dogs, or even 
survival beyond 30 days after liver replace-
ment, there was growing suspicion that 
there might be some fundamental difference 
in rejection of the liver which made this 
organ more difficult to protect. 
After Porter's visit to Colorado in Sep-
tember 1963, 150 canine liver transplanta-
tions were performed at the rate of four per 
week at the Denver VA research 
laboratories with weekly or twice weekly 
shipments of the resulting tissues to Lon-
don. One of the liver recipients from the 
series (84) lived for almost 12 years before 
dying of old age. Half of the animals treated 
with Imuran lived for 25 to 50 days and 
about one in five survived three months or 
longer. The results were better than with 
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dog kidney transplantation, using Imuran 
alone. At a greater frequency than after kid-
ney transplantation, it was possible to stop 
treatment after three or four months without 
evidence of subsequent rejection (85). 
The possibility was raised for the first 
time that rejection of the liver might be 
easier to control than that of other organs 
(84,85). Subsequently, much stronger 
evidence that this was true was provided 
from pig experiments by Garnier (86), 
Peacock (87), and Caine (88). The 
pathologic studies by Porter filled in other 
missing information (89). He redefined the 
features of acute rejection, delineated those 
of chronic rejection, and laid the basis for 
needle biopsy interpretation which became 
a cornerstone of modern management of 
liver transplant recipients. 
These liver transplant experiments set-
tled the issue of feasibility but not of prac-
ticality. For human cases, all livers would 
have to come from cadaveric donors. 
These nonrelated organs would be more 
difficult to protect from rejection than the 
"easy" intrafamilial human kidney transplan-
tations that had fanned our enthusiasm in 
1962 and 1963. The next project was the 
development of ALG. 
Ken Porter was the person who sug-
gested the ALG project. He knew of work in 
progress on antilymphocyte serum (ALS) in 
rats by Michael Woodruff and Keith James 
of Edinburgh and by other workers in 
Britain. The principles of ALS therapy had 
been known since the time of Metchnikoff 
who immunized guinea pigs with rat lymph 
nodes or spleen cells and then demon-
strated that the guinea pig sera lysed rat 
monocytes (90). With a flash of clair-
voyance Metchnikoff suggested the use of 
such sera to eliminate the cell lines guilty of 
causing certain human diseases (later 
shown to be autoimmune). Sixty years 
later, the pursuit of this fantasy would take a 
detour through transplantation. 
In modern times, ALS preparations to 
prevent experimental skin graft rejection 
were first used at Yale University (Byron 
Waksman) (91), Edinburgh (Michael 
Woodruff) (92), and at Harvard (Tony 
Monaco and Paul Russell) (93). A tidal 
wave of publications followed including 
those from Medawar's laboratory (94). In 
these experiments, rabbits were immunized 
against the lymphocytes of mice, guinea 
pigs, or rats. The rabbit serum was injected 
intraperitoneally in the treated animals. 
Skin grafts placed between mice, between 
guinea pigs, or between rats survived for 
prolonged periods. 
The infusion or injection of raw animal 
serum into humans was not a particularly 
palatable idea, especially when the dosage 
into the abdomen would be several gallons 
if the experimental information was applied 
to clinical practice. In addition, a larger 
animal than the rabbit would be preferable 
in which to raise the antibodies against 
human lymphocytes. The horse was a can-
didate. Finally, there was no reason to give 
the whole animal serum to patients when 
the antibody activity was presumably limited 
to some small fraction of which the location 
was suspected but not proved. 
By the end of 1965, we were far along 
in research on ALS but with a different pur-
pose than the purely scientific ones being 
pursued in most other laboratories. We 
were gearing up for clinical trials. We had 
selected the horse as a serum donor, iden-
tified the gamma globulin as the target for 
refinement of the antilymphocytic antibodies 
in the horse serum, learned how to remove 
and purify this fraction which we called an-
tilymphoid globulin (ALG), and devised test 
tube analyses which would allow us to es-
timate its potency. The leader of this re-
search team was Yogi Iwasaki, a Japanese 
surgeon who today is Chairman of the 
Department of Surgery at Tsukuba Univer-
sity near Tokyo (95). When he returned 
home, he sent another surgeon, Noburu 
Kashiwagi to take his place (96). Kashiwagi 
now is Professor of Experimental Surgery at 
Kitasato University. 
Every step in the process and its 
totality were tested in the dog with both kid-
ney and liver transplantation (97). For 
these animal experiments, dog ALG was 
prepared using dog spleen and lymph 
nodes to immunize the horse. For human 
ALG, the spleens and lymph nodes were 
taken from fresh cadavers, and the lym-
phocytes for injection into the horse were 
removed from these tissues in much the 
same way as must have been used by 
Metchnikoff two-thirds of a century earlier. 
In June and July, 1966, the first 
patients in the world to be treated with ALG 
could be picked out of a crowd of their 
transplant peers at the Colorado General or 
Denver Veterans Administration Hospitals. 
The ALG was given into the muscles of the 
buttock and caused such severe pain and 
swelling that the patients constantly walked 
the floors trying to rid themselves of what 
felt like a charley horse. They sat crookedly 
on chairs and formed their own support 
group to exchange tall tales and especially 
complaints. 
The trial was a success (97,98). Rejec-
tion was practically eliminated during the 
period of ALG therapy if treatment was 
started at the time of transplantation. If ALG 
treatment was delayed, it could be used ef-
fectively to reverse established rejection. 
The amounts of Imuran and prednisone 
(especially the latter) were reduced. This 
was the beginning of the triple-drug im-
munosuppression (Imuran-prednisone-ALG) 
which was the new plateau from which liver 
transplantation could start again. Not far 
behind would come the heart. 
Later, improvements were made in ALG 
therapy. Purer preparations of human lym-
phocytes could be obtained by collecting 
them from the thoracic duct during thoracic 
duct drainage (Traeger of Lyon), from the 
thymus, or by culturing them. The techni-
que of lymphocyte culture was developed 
by George Moore of Roswell Park Hospital, 
Buffalo and applied by John Najarian, 
Richard Condie, and Richard Simmons at 
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the University of Minnesota. Also, the ALG 
could be given intravenously, eliminating the 
intramuscular injection pain which for some 
patients was almost unendurable. 
The limitations of ALG were defined al-
most immediately (97-99). It was not a drug 
like Imuran or prednisone which could be 
used for chronic treatment because of im-
mune reactions against the injected horse 
protein. A penalty for the use of ALG was a 
higher incidence of virus infections including 
those (Epstein-Barr) associated with lym-
phoma formation. What we had ac-
complished was a significant but not a 
quantum improvement in patient care. 
Ben Cosimi, one of our Colorado medi-
cal students, assisted with the development 
of ALG for human use before leaving for the 
Massachusetts General Hospital in July 
1964 to begin his surgical training. His 
dream of producing a more practical and 
safer ALG came within reach when Kohler 
and Milstein developed the hybridoma tech-
nology (1 OO). With it, Gideon Goldstein and 
Cosimi produced OKT3, a modern version 
of ALG, and began its clinical use in 1980 
(101). 
Improved immunosuppression and a 
better understanding of tissue matching 
were justifications for resumption of clinical 
liver transplant trials. There remained the 
problems of the liver donor and liver preser-
vation. Preservation technology for all or-
gans began with liver transplant research in 
the late 1950s. The first innovation of core 
cooling by infusion of chilled lactated 
Ringer's solution into the portal vein was 
the most important (31). This was the first 
time hypothermia was induced by the in-
travascular infusion of cold flUids. Earlier it 
had been appreciated by cardiac surgeons 
that hypothermia protected ischemic tissue 
below the level of aortic-clamping (102). 
Hypothermia to protect human renal 
homografts was first accomplished with total 
body hypothermia of living volunteer donors 
(44) , but before long we replaced this cum-
bersome and potentially dangerous method 
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with infusion of chilled fluid into the kidney 
immediately after its removal (103). It was 
a simple and overdue transfer of technology 
from the laboratory. 
Today, core cooling is the first step in 
the preservation of all whole organ cadaver 
grafts and this is most often done in situ by 
some variant of the technique observed by 
Goodwin (see earlier) in May 1963 during 
his visit to Colorado (56,57). This method 
for the continuous hypothermic perfusion of 
cadaveric livers and kidneys was used clini-
cally long before the acceptance of brain 
death conditions. Later Ackerman and Snell 
(104) and Merkel, Jonasson, and Bergan 
(105) popularized in situ cooling of 
cadaveric kidneys with cold electrolyte solu-
tion infused into the distal aorta. Two 
decades later, in situ cooling was refined to 
allow removal of all thoracic and abdominal 
organs, including the liver, without jeopard-
izing any of the individual organs (106,107). 
When the final versions of these so-called 
flexible techniques of procurement were 
published in the 1980s, they quickly be-
came a worldwide standard. 
Extension of the safe period beyond 
that provided by initial cooling and 
avoidance of warm ischemia has followed 
one of two prototype strategies. The ap-
proach of providing a limited and continuous 
hypothermic circulation was refined to iso-
lated organ perfusion by Ackerman and Bar-
nard (108) who used a perfusate containing 
blood. The perfusate was oxygenated 
within a hyperbaric oxygen chamber. The 
same method with slight modifications also 
permitted the successful preservation of 
dog livers for as long as two days (109) and 
was applied clinically with remarkable suc-
cess in several human cases in the pre-
brain death era after preliminary total body 
cooling with extracorporeal perfusion (110). 
The isolated liver perfusion project was 
headed by Larry Brettschneider, a 30-year-
old surgeon and Lieutenant Commander in 
the United State Navy who was detached to 
Colorado for two years, beginning in early 
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1966. The technique was ready for clinical 
use by the end of the year. It may be that 
this was the best method of liver preserva-
tion used to the 1990s. However, the hy-
perbaric chamber was cumbersome and 
extremely heavy. The pilots who flew us in 
small planes to donor cities on the other 
side of the Rocky Mountains were terrified 
that it would roll through the side of the 
aircraft like a lead ball, or explode from its 
high internal pressure. Later, when brain 
death was accepted, it never was used 
again. 
Yet, it played a role. This was the tech-
nique that was used to preserve all of the 
first successfully transplanted human livers 
in 1967 and 1968. Brettschneider died 
tragically in 1978. When Belzer et al (111) 
were able to eliminate the hemoglobin and 
hyperbaric chamber components for kidney 
preservation, their asanguinous perfusion 
technique became a worldwide standard. 
However, efforts to use this modification for 
livers were unsuccessful (112). 
The alternative strategy for the preser-
vation of kidneys, livers, and other organs 
after initial cooling also had its origin in this 
era. This was the instillation of special solu-
tions such as that described by Collins, 
Bravo-Shugarman, and Terasaki (113) or 
the plasma-like Schalm solution eventually 
used by Caine (114). The original Collins 
solution, or modification of it, was used for 
almost two decades for the so-called "slush" 
techniques of kidney preservation. The ex-
perimental work of Benichou et al (115) and 
Wall et al (116) with the Collins and Schalm 
solutions preceded their first clinical use for 
livers in 1976 which opened up the pos-
sibility of organ sharing between cities, but 
within narrow time limitations. 
The introduction of the UW solution 
was the first major development in liver 
preservation since then. The superiority of 
the UW solution to any of previous "conven-
tional" solutions for preservation of liver and 
extrahepatic organs has been demonstrated 
in experimental test models (117) and 
quickly confirmed in clinical trials (118,119) 
during the late 1980s. The advance with 
the liver was then applied to other organs. 
One other project of this phase 
developed a life of its own which continues 
to expand 25 years later. This was an ex-
ploration of the optimum conditions for the 
transplantation of an extra (auxilary) liver at 
some ectopic site, leaving the diseased na-
tive liver in place. Reexamination was re-
quired of the mysterious Eck fistula 
(portacaval shunt) and the possible interac-
tion between pancreatic insulin and the liver 
which had been my entry point into 
transplantation in 1956 (see earlier). The 
liver shrinkage caused by portacaval shunts 
in dogs [and also in rats, baboons, and 
humans (120)] and the wasting, hair loss 
and brain damage that foil ow were ascribed 
until the mid 1960s to the loss of portal 
blood flow rather than the loss of exposure 
to the liver of any specific substance(s) in 
the portal blood (121-123). This became 
known as the flow hypothesis of portal 
physiology. Yet, an uneasiness about this 
glib explanation could be sensed in an 
otherwise authoritarian review article written 
in 1961 by J. L. Boilman of the Mayo Clinic 
(124) who wrote, "In the 83 years since it 
was first reported the Eck fistula has been 
reasonably successful in hiding its secrets 
as weil as giving rise to many additional 
questions fundamental to an understanding 
of the functions of the intestine, liver and 
brain." 
The secrets referred to by Boilman 
finally were unmasked by auxiliary liver 
transplant studies in dogs which were 
begun in 1963. This operation was 
described in 1955 by Welch in what was the 
first mention of liver transplantation in the 
medical literature (125). Our experiments 
eight years later showed that coeXisting 
livers competed with each other for some 
substrate(s) or nutritional substance(s) 
(57,126). From 1963 onward, it was clear 
that when two livers were present, the one 
with primary access to portal venous flow 
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would thrive because it consumed some-
thing in the portal blood, whereas the other 
liver would atrophy. This dictated the tech-
nical conditions for auxiliary liver grafts. 
Their portal venous inflow would require 
blood from the splanchnic venous bed. It 
was concluded that portal blood contained 
"hepatotrophic" factors, but the identity of 
these mysterious substances was unknown 
at first. 
To find out, definitive non-transplant ex-
perimental models were designed in which 
the animal's own liver was divided into two 
parts, each of which could be given the 
venous blood that came from different or-
gans or different parts of the body (127-
131). Later, experiments were done in 
which the effect on the liver of removing 
these organs was tested. All of the testing 
done from 1971 onward showed that the 
most potent (although not the only) 
hepatotrophic factors were from the 
pancreas. In the end, it was demonstrated 
that insulin when injected alone into the al-
tered liver circulation could prevent the 
atrophy and most of the consequences to 
the liver that were caused by the Eck fistula 
(132). 
This was the death blow to the portal 
flow hypothesis and the beginning of a new 
concept about the interactions of the liver 
with the pancreas and other abdominal or-
gans. The role of insulin as a liver growth 
control factor was established, as well as a 
new field of hepatotrophic physiology (133). 
The concept was that the pancreas (par-
ticularly its insulin) and other less important 
but cumulatively significant substances from 
the viscera modulated hepatic structure, 
function, and capacity for regeneration. The 
metabolic interrelationships of intraab-
dominal organs was to become a con-
sideration in the technical planning for 
transplantation of any of these organs and 
particularly the transplantation of multiple 
abdominal viscera. Ultimately, the multivis-
ceral operation which had evoked bemuse-
ment in 1960 (36,37) became the starting 
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point for variations which permitted the suc-
cessful transplantation of bowel for the first 
time (134-136). 
In addition, the original experimental 
techniques developed to uncover the insulin 
effects were applied almost two decades 
later to show that cyclosporine and FK 506 
also have hepatotrophic properties including 
the augmentation of hepatic regeneration 
(137-139). These drugs and others includ-
ing rapamycin bind to ubiquitous small 
molecular weight cytosolic proteins called 
immunophilins (140,141) and are thought to 
act by disrupting normal signal transduction 
pathways (142), but not only in cells with 
immunologic function (139). Recognition of 
the pleiotropic function (including growth 
control) of the immunophilin network 
(139,142,143) is the latest example of a rip-
ple (or tidal wave) effect in basic science 
laboratories of clinically directed research in 
transplantation. 
During 1964 to 1966, the Denver VA 
Hospital laboratory was like Grand Central 
Station. One visitor, Chris Barnard, was no 
casual tourist. Barnard spent the better part 
of a year in the United States at three 
centers: in Richmond with Dick Lower and 
Dave Hume who told me later that Barnard 
had seemed interested mainly in learning 
how to treat rejection, in Colorado (autumn 
1966) where he focused his attention on the 
ALG project, and in Palo Alto where he 
visited Shumway whom he had known 
since their earlier days at the University of 
Minnesota. I told Barnard candidly that we 
were planning to go ahead with heart 
transplantation in Denver but not until we 
were successful with the liver. I assumed 
that he was going to start a kidney program 
in Capetown and so did the others whom he 
visited. 
PHASE V (1967 to 1969) 
With the support struts of Phase V in 
place, the time had come to resume the 
clinical trials of orthotopic liver transplanta-
tion (liver replacement). Procurement of 
livers was from "heart dead" donors. All of 
the recipients had triple-drug immunosup-
pression with Imuran, prednisone, and ALG. 
The seven new patients (all children) 
passed through the lethal period en-
countered during and just after liver 
transplantation in the 1963 cases. Four 
died after two, three and one-half, four and 
one-third, and six months. All other com-
plications were trivial compared to the one 
which caused their deaths. This was the 
development of gangrene of a portion of the 
transplanted livers, the other part of which 
continued to function properly. The dead 
portion of the liver was infected with bac-
teria normally found in the intestine. 
The other three children remained alive 
for 13, 15, and 30 months, long enough to 
demonstrate convincingly the potential 
value of this kind of treatment (144). Two of 
the three late deaths were caused by recur-
rence of the hepatomas which had been the 
reason for the transplantation; the third died 
of chronic rejection. By the time the last 
patient died, another child was a half year 
into a new life that now is well into the twen-
ty-second posttransplant year (145). This 
recipient had biliary atresia but in her 
removed liver was found a small cancer 
which had not been suspected in advance. 
It never came back. 
Carl Groth of Stockholm helped 
operate on and care for all of these patients. 
Before he returned to Sweden in March 
1968, he helped complete an investigation 
in dogs (146) which was based on his ob-
servations in the children who developed 
partial gangrene of the liver graft. The 
study showed that an important factor 
predisposing to liver infection was under-
treatment with immunosuppression with 
consequent rejection. In turn, a reduction in 
liver blood flow caused by rejection pre-
viously had been demonstrated by Groth 
(147), to set the stage for oxygen starvation 
of the transplanted liver and a consequent 
lowered resistance to bacteria. Paradoxi-
cally, the best way to prevent this was more 
vigorous anti rejection treatment in spite of 
the consequent depression of systemic 
resistance to infection (148). 
The prolonged survival of the first 
children in the series became known 
worldwide by September 1967. The ripple 
effect went beyond the liver. Penetration of 
the barrier which had precluded extension 
of transplantation operations beyond the 
relatively simple kidney fanned the embers 
in other organ-defined specialities. By the 
end of the year, Barnard of Capetown had 
performed the first heart transplantation 
(149), followed shortly by the beginning of 
Shumway's clinical program at Stanford 
(150). Responding to phone call requests, 
we became the suppliers of homemade 
ALG for these and other heart programs 
which followed. 
Within a year, the first successful lung 
transplantation was performed by Derom of 
Louvain (151) and the first pancreas and in-
testinal transplants were attempted by Lil-
lehei and Kelly of the University of 
Minnesota (152,153). Most of the attempts 
with all of the extrarenal organs failed. 
When the rush of enthusiasm was replaced 
by reality, only a few diehards were left. 
Further clinical development of hearts would 
be at Stanford. The pancreas would 
depend upon Carl Groth in Stockholm, Jean 
M. Dubernard of Lyon, and Dave Suther-
land of Minneapolis. Lung transplantation 
lay dormant for almost 15 years until Joel 
Cooper of Toronto finally established its 
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practicality. Intestinal transplantation was 
abandoned for almost two decades. 
Liver transplantation continued in 
Cambridge (Caine) and Denver. By early 
February 1969 we had treated 20 patients 
since the 1967 reinstitution of the liver re-
placement trials. For one, a chimpanzee 
was the donor. Only seven of the patients 
survived for more than one year. The con-
clusion was inescapable. Liver transplanta-
tion was a feasible but impractical way to 
treat end stage liver disease. This was the 
picture presented in a second book, Ex-
perience in Hepatic Transplantation (154), a 
companion piece to the earlier Experience 
in Renal Transplantation (61). The liver 
book was written with Charley Putnam, then 
a senior medical student at Northwestern 
and now a Professor of Surgery (in the 
same department as Charlie Zukowski) at 
the University of Arizona. 
In the new book, every known clinical 
attempt made at liver transplantation in the 
world (orthotopic and auxiliary) and every 
experimental paper written on the subject 
up to early 1969 were included. The book 
portrayed liver transplantation more pes-
simistically than it would actually be during 
the following 10 years. Yet, more recipients 
died than lived throughout this time. Al-
together, 170 patients were treated between 
1963 and the end of 1979 (145). Only 29 
(16.5 percent) still survive. Now, they are 
11 to 21 and one-half years posttransplanta-
tion. In England, Caine maintained the only 
other sustained liver transplant program 
which was opened in May 1967 (155). As in 
Colorado, these efforts created controversy. 
Caine became a European voice in the 
wilderness. 
PHASE VI (1970 -
If it had not been for the 1960s, 
transplantation would have remained a 
fancy, and if it were not for the 1980s, it 
would have remained a starveling. In be-
tween was the time for those thousands of 
details to be clarified which had been 
skipped in the rush to the finish line; a time 
to explain why the beachhead known as 
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transplantation had become a slowly erod-
ing revetment; and a time to look for some-
thing better. ALG had had a smaller than 
expected impact on transplantation 
worldwide because of the necessity for its 
temporary use only and because of 
problems with its manufacture, stand-
ardization, and testing. Only about 15 per-
cent of cadaver kidney transplantations 
worldwide were done with ALG treatment. 
The results with cadaver kidney 
transplantation remained fixed at an un-
satisfactory level (64,156-158). Trapped 
now by their own partially successful efforts, 
surgeons interested in the extrarenal organs 
brooded in their self-made dungeons, 
smuggling messages to each other or com-
municating by secret Signals, tapped on 
their academic cell walls. There were very 
few left who continued to try. Then the way 
out of the dilemma came with cyclosporine. 
The drug was discovered by workers at the 
Sandoz Corporation and shown by Jean 
Borel to weaken immunologic responses in 
a variety of test systems including that of 
skin graft rejection in mice (159). 
In England, Caine and his Cambridge 
team evaluated cyclosporine for the 
transplantation of a variety of whole organs 
(kidney, heart, liver, pancreas) in rats, dogs, 
and pigs. These experiments led directly to 
the first human trials in kidney transplanta-
tion at Cambridge, beginning in the late 
spring of 1978 (160,161). At first, it was 
hoped that cyclosporine could be used as 
single-drug therapy, but it too was destined 
to be part of cocktail regimens in which 
steroids were the most dose maneuverable 
component (162) and to which azathioprine, 
ALG, and other agents could be added. 
Cadaver kidney transplantation finally 
reached the level of a legitimate clinical ser-
vice. Transplantation of the liver (145,163) 
and soon after the other extrarenal organs 
was revolutionized overnight. For me, most 
of this new era was at the University of Pit-
tsburgh, where I moved in December 1980. 
Liver transplantation was made easier by a 
modern day version of vena-venous bypass 
(145,164,165). The liver and heart 
transplant gold rush dwarfed what had hap-
pened with the kidney in 1964. 
With the revolution came a downside. 
In addition to its marvelous qualities, 
cyclosporine had side effects which had 
been described by Caine as early as 1979 
(161). The most serious were nephro-
toxicity and hypertension in the majority of 
reCipients of all kinds of organs. 
Nephrotoxicity, hirsutism, gum hyperplasia, 
neurotoxicity, and other less serious side ef-
fects were dose-related. When the doses 
were reduced to relieve them, the risk of 
rejection increased. Transplant surgeons 
with an obsession for perfection were less 
interested in working around these 
problems than in finding a more fundamen-
tal solution. FK 506, a macrolide antibiotic 
which was discovered in 1984 and first 
reported in 1987 (166-168) is the most 
promising new agent. Extensive clinical tri-
als were begun in 1989 (169). 
With the advances of the last decade, it 
has become possible to improve the kinds 
of transplantation (liver, heart, pancreas) 
which were feasible but not practical and to 
succeed with previously "forbidden" 
transplants of pancreatic islets (170), intes-
tine (171,172), and multivisceral organs 
containing intestine (134-136). The relative 
"acceptance" of solid organ grafts in many 
patients still is not understood, but a recent 
clue has been the demonstration of post-
operative Iymphoreticular repopulation of 
human intestinal grafts with recipient cells. 
This means that transplanted organs 
can become "composites," possibly helping 
to explain why the need for chronic im-
munosuppression may recede in successful 
clinical transplantation of all organs, not just 
those which are rich in lymphoid tissue. 
Such cell repopulation was first noted by 
Porter more than two decades ago in the 
macrophage system of human liver 
homografts (89). Thirty years ago, in 
describing what they called graft adaptation, 
Michael and Hazel Woodruff had asked if 
thyroid transplants underwent some kind of 
change which explained their acceptance 
by the host if they could be protected from 
rejection at the outset (173). 
In hepatic grafts whose composite 
structure has been known for more than two 
decades (89), it was established in 1964 
(58) that the graft metabolic specificity was 
retained as shown by the replacement of 
recipient haptoglobin phenotypes with those 
of the donor. This simple observation was 
the basis for the treatment with liver 
transplantation of numerous inborn errors of 
metabolism, now numbering nearly two 
dozen (174). The metabolic correction lasts 
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for the lifetime of the graft. Every few 
months, a new disease is added to the list. 
Now half-forgotten ideas were being 
reexplored, and burned-out camp sites were 
being rediscovered, as had occurred with 
those who arrived in the 1950s. When 
mountains are climbed by different people, 
the triumph can be spoiled by asking who 
took the first step to the summit, who took 
the longest stride, and most insidiously who 
did not. All of those who made the clinical 
transplant journey of the last 40 years found 
footprints, which like those in the snow in 
the high mountain reaches, do not melt. No 
matter how early the transplant explorer's 
arrival, someone already had been there, at 
least part way. 
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